MedVasc
MedVasc AB is a Swedish medtech company developing the Solutio™ catheter, a single-injection intravascular anesthesia delivery device used during thermal ablation treatment of varicose veins. The pre-commercialization company targets vascular surgeons, interventional radiologists, and vein treatment centers, with FDA 510(k) clearance and US market entry planned for autumn 2026.
- Company typePrivate
- Founded2013
- HeadquartersLund, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MedVasc does
MedVasc AB is a privately held Swedish medtech company founded in 2013 and headquartered at Medicon Village in Lund, Sweden. The company is developing a single asset, the Solutio™ catheter system, a patented device that delivers tumescent local anesthesia from inside the vein through a single injection during endothermal (thermal ablation) treatment of varicose veins, replacing the multiple skin injections currently required. The technology is designed to be compatible with a broad installed base of existing thermal ablation treatment catheters, and a first-in-man clinical study demonstrated safety and significantly reduced pain during anesthesia deployment. The founder, Dr. Michael Åkesson, is the named inventor, and the technology is protected by granted patents across the US, Europe, China, India, Canada, Brazil, Australia, South Africa, and Russia, with the Solutio trademark registered worldwide.
MedVasc is a pre-commercialization development-stage company with 1–10 employees. Revenue will be generated through hardware sales of the Solutio catheter to healthcare providers, specifically vascular surgeons, interventional radiologists, phlebologists, and the hospitals and outpatient vein treatment centers where they practice, once regulatory clearance is obtained. Distribution is planned as direct sales to US hospitals and clinics post-approval, with the company currently investing in conference presence (Veith Symposium, American Venous Forum, European Venous Forum, International Venous Conference) and accelerator programs (Medtronic/MedLim, Innovate Nordics 2026) to build clinical awareness, KOL advocacy, and US market entry infrastructure.
The company has raised approximately SEK 48 million cumulatively across multiple rounds between 2019 and 2025, with a SEK 24 million (~€2.2 million) financing completed in late 2025 from existing shareholders to fund remaining FDA 510(k) clearance activities. MedVasc initiated the FDA 510(k) pathway in 2023 and is targeting regulatory submission in the first half of 2026 with clearance expected in autumn 2026, positioning the US as the lead commercial market. The company operates from a single Swedish site, participates in the SmiLe life science incubator in Lund, and has assembled a US Advisory Board of recognized venous and vascular KOLs to support US market entry.
MedVasc firmographics
Firmographics- Name
- MedVasc
- Legal name
- MedVasc AB
- Website
- https://medvasc.se
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MedVasc AB is a Swedish medtech company developing the Solutio™ catheter, a single-injection intravascular anesthesia delivery device used during thermal ablation treatment of varicose veins. The pre-commercialization company targets vascular surgeons, interventional radiologists, and vein treatment centers, with FDA 510(k) clearance and US market entry planned for autumn 2026.
- Ownership category
- akta.pro rank
MedVasc industry classification
Industry- Product category
- Vascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)
- akta.pro secondary industries
- Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs) (HLAHANAG), Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)
Keywords
Where MedVasc is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
MedVasc business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Medical Device Sales: Pre-commercialization medical device company developing Solutio™ anesthesia catheter for varicose vein treatment. Revenue will be generated through sales of the catheter device to healthcare providers and hospitals upon FDA approval and market entry.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels5 records
MedVasc product offering
Product offeringCore offering
MedVasc develops and manufactures the Solutio catheter system, a patented intravascular medical device that delivers tumescent local anesthesia from inside the vein during endothermal treatment of varicose veins. The single-injection design replaces multiple skin injections, reducing patient pain and improving procedural efficiency for vascular surgeons, interventional radiologists, and phlebologists. The product is currently pre-commercialization and pursuing FDA 510(k) clearance for U.S. market entry in autumn 2026.
Product overview
MedVasc is a single-product medtech company focused on vascular access technologies for minimally invasive procedures. Its flagship offering is the Solutio™ catheter, a novel anesthesia delivery device designed to enable tumescent local anesthesia from inside the vein during endothermal treatment of varicose veins. The product is currently under development and pending FDA 510(k) clearance for the U.S. market, with regulatory submission planned for the first half of 2026 and market approval expected in autumn 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- Solutio Catheter A novel anesthesia catheter designed to deliver tumescent local anesthesia from inside the vein during endothermal treatment of varicose veins. The single-injection technology enables precise local anesthesia, reducing pain for patients and improving efficiency for clinicians during thermal ablation procedures. It is compatible with a broad range of existing thermal ablation treatment catheters on the market.
Quantifiable outcome
- First-in-man clinical study demonstrated Solutio is safe to use while significantly lowering pain during local anesthesia deployment for thermal ablation of varicose veins
Companies that use MedVasc
Customer profileSegments2 records
Ideal customer profiles2 records
MedVasc technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
MedVasc partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Medtronic / MedLim Accelerator ProgramcoreMedVasc was selected as 1 of 11 international medtech startups to participate in accelerator program powered by Medtronic and MedLim partners in Maastricht, Netherlands. The program focused on learning how to accelerate commercialization through digital sessions and 1-1 meetings with Medtronic partners.
- Swedish-American Chamber of Commerce / EY (Innovate Nordics 2026)coreMedVasc selected for Innovate Nordics 2026 accelerator hosted by Swedish-American Chamber of Commerce in New York in partnership with EY. Program provides strategic workshops, investor engagement, pitch training, and introductions to key stakeholders across the US healthcare ecosystem for Nordic life science companies preparing for US expansion.
- SmiLe IncubatorminorMedVasc participates in SmiLe's Lund-based incubator programme, a life science business incubator supporting company development and growth.
- DrägerminorLeading international medical and safety technology company (DAX-listed, family-run since 1889) hosted the MedTech Pitch Day 2025 event in Lübeck, Germany.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
MedVasc competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Through its acquisition of Covidien/VNUS Closure and via the Medtronic-powered accelerator that selected MedVasc, Medtronic is both a competing thermal ablation franchise owner and a strategic partner. It represents the dominant incumbent in the endovenous ablation market Solutio serves.
- Boston Scientific: Large diversified medtech with a peripheral vascular and venous intervention portfolio. Comparable as a broad incumbent operating in the same endovenous procedure channel where Solutio would be used.
- Smiths Medical (ICU Medical): ICU Medical acquired Smiths Medical, combining anesthesia delivery and vascular access product lines. Comparable as an incumbent offering catheter-based drug and anesthesia delivery devices that compete for the same clinical workflow Solutio targets.
- Merit Medical Systems: Manufactures a broad portfolio of disposable vascular access and procedure consumables used in interventional procedures. Comparable to MedVasc as a single-use catheter consumable manufacturer selling into the same hospital/ASC call points.
- B. Braun: Global manufacturer of infusion, anesthesia delivery, and vascular access consumables. Comparable to MedVasc as an established player in the anesthesia/infusion catheter space that Solutio's intravascular delivery technology overlaps with.
- BD (Bard Medical): BD acquired Venclose, a varicose vein ablation catheter developer, and is a major manufacturer of vascular access and catheter consumables. Directly comparable as a broad medtech incumbent in both venous intervention and single-use catheter consumables.
- Teleflex: Acquired Vascular Solutions and maintains a portfolio of venous and procedural consumables used in vascular procedures. Relevant because Teleflex sells into the same hospital call points MedVasc plans to target post-FDA.
Emerging players
- Inari Medical: Focused on venous thromboembolism intervention with dedicated venous catheters. Comparable as a newer, venous-specialized medtech that grew rapidly on the back of a focused venous device portfolio and KOL relationships.
- Penumbra: Vascular and venous thrombectomy device company that scaled a focused catheter portfolio into a publicly traded medtech. Comparable as a recent emerging player whose trajectory illustrates the upside path for venous-focused catheter companies.
Direct peers
- AngioDynamics: Markets ClosureFast endothermal ablation catheters and other venous treatment devices. Direct adjacency to MedVasc because Solutio is used during the same thermal ablation procedures that ClosureFast performs, making AngioDynamics the most relevant incumbent counterpart.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
MedVasc social profiles
Digital presenceMedVasc financial estimates
Financial estimateRevenue estimate
Valuation estimate
MedVasc leadership team
Management profileNumber of profiles
Profiles14 records
MedVasc funding detail
Funding detailFunding overview
Funding rounds8 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MedVasc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MedVasc
What does MedVasc do?
MedVasc develops and manufactures the Solutio catheter system, a patented intravascular medical device that delivers tumescent local anesthesia from inside the vein during endothermal treatment of varicose veins. The single-injection design replaces multiple skin injections, reducing patient pain and improving procedural efficiency for vascular surgeons, interventional radiologists, and phlebologists. The product is currently pre-commercialization and pursuing FDA 510(k) clearance for U.S. market entry in autumn 2026.
Is MedVasc a public or private company?
MedVasc is a private company. It is classified as venture growth investor backed and is currently operating.
When was MedVasc founded?
MedVasc was founded in 2013. It employs 1 to 10 people.
Where is MedVasc based?
MedVasc is headquartered in Lund, Sweden, in the Europe region.
How does MedVasc make money?
One revenue line is on record: medical Device Sales.
Who are MedVasc's main competitors?
Broad incumbents on record are Medtronic, Boston Scientific, Smiths Medical (ICU Medical), Merit Medical Systems, B. Braun, BD (Bard Medical) and Teleflex. Emerging players are Inari Medical and Penumbra. AngioDynamics is listed as a direct peer.
Does MedVasc have an API?
No public API is recorded for MedVasc.
What industry is MedVasc in?
MedVasc's product category is Vascular Medical Devices. Its primary akta.pro industry code is HLAHAIAH, Infusion Sets, Catheters & Pump Consumables, with a secondary code of HLAHANAG, Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs). Its NAICS code is 339112 and its SIC code is 3841.